| Title |
HIV-Associated Neurocognitive Disorder: Pathogenesis and Therapeutic Opportunities
|
|---|---|
| Published in |
Journal of Neuroimmune Pharmacology, April 2010
|
| DOI | 10.1007/s11481-010-9205-z |
| Pubmed ID | |
| Authors |
Kathryn A. Lindl, David R. Marks, Dennis L. Kolson, Kelly L. Jordan-Sciutto |
| Abstract |
Human immunodeficiency virus type 1 (HIV) infection presently affects more that 40 million people worldwide, and is associated with central nervous system (CNS) disruption in at least 30% of infected individuals. The use of highly active antiretroviral therapy has lessened the incidence, but not the prevalence of mild impairment of higher cognitive and cortical functions (HIV-associated neurocognitive disorders) as well as substantially reduced a more severe form dementia (HIV-associated dementia). Furthermore, improving neurological outcomes will require novel, adjunctive therapies that are targeted towards mechanisms of HIV-induced neurodegeneration. Identifying such molecular and pharmacological targets requires an understanding of the events preceding irreversible neuronal damage in the CNS, such as actions of neurotoxins (HIV proteins and cellular factors), disruption of ion channel properties, synaptic damage, and loss of adult neurogenesis. By considering the specific mechanisms and consequences of HIV neuropathogenesis, unified approaches for neuroprotection will likely emerge using a tailored, combined, and non-invasive approach. |
Mendeley readers
The data shown below were compiled from readership statistics for 217 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Germany | 1 | <1% |
| South Africa | 1 | <1% |
| India | 1 | <1% |
| Canada | 1 | <1% |
| United States | 1 | <1% |
| Unknown | 212 | 98% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Ph. D. Student | 37 | 17% |
| Student > Bachelor | 30 | 14% |
| Student > Master | 29 | 13% |
| Researcher | 23 | 11% |
| Student > Postgraduate | 15 | 7% |
| Other | 47 | 22% |
| Unknown | 36 | 17% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 66 | 30% |
| Agricultural and Biological Sciences | 39 | 18% |
| Neuroscience | 19 | 9% |
| Psychology | 17 | 8% |
| Biochemistry, Genetics and Molecular Biology | 9 | 4% |
| Other | 24 | 11% |
| Unknown | 43 | 20% |
Attention Score in Context
This research output has an Altmetric Attention Score of 14. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 06 November 2017.
All research outputs
#2,451,240
of 24,217,893 outputs
Outputs from Journal of Neuroimmune Pharmacology
#65
of 583 outputs
Outputs of similar age
#7,669
of 82,714 outputs
Outputs of similar age from Journal of Neuroimmune Pharmacology
#2
of 8 outputs
Altmetric has tracked 24,217,893 research outputs across all sources so far. Compared to these this one has done well and is in the 89th percentile: it's in the top 25% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 583 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 10.7. This one has done well, scoring higher than 88% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 82,714 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 90% of its contemporaries.
We're also able to compare this research output to 8 others from the same source and published within six weeks on either side of this one. This one has scored higher than 6 of them.